These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 38582393)

  • 1. Exploring ncRNA-mediated regulation of EGFR signalling in glioblastoma: From mechanisms to therapeutics.
    Thapa R; Afzal M; Goyal A; Gupta G; Bhat AA; Almalki WH; Kazmi I; Alzarea SI; Shahwan M; Kukreti N; Ali H; Dureja H; Kumar P; Singh TG; Kuppusamy G; Singh SK; Dua K
    Life Sci; 2024 May; 345():122613. PubMed ID: 38582393
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Non-coding RNAs (ncRNAs) and multidrug resistance in glioblastoma: Therapeutic challenges and opportunities.
    Subaiea GM; Syed RU; Afsar S; Alhaidan TMS; Alzammay SA; Alrashidi AA; Alrowaili SF; Alshelaly DA; Alenezi AMSRA
    Pathol Res Pract; 2024 Jan; 253():155022. PubMed ID: 38086292
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MicroRNAs involved in the EGFR pathway in glioblastoma.
    Xu B; Mei J; Ji W; Huo Z; Bian Z; Jiao J; Li X; Sun J; Shao J
    Biomed Pharmacother; 2021 Feb; 134():111115. PubMed ID: 33341046
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The emerging role of noncoding RNAs in the EGFR signaling pathway in lung cancer.
    Mohan S; Hakami MA; Dailah HG; Khalid A; Najmi A; Zoghebi K; Halawi MA
    Pathol Res Pract; 2024 Jan; 253():155016. PubMed ID: 38070221
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Non-coding RNAs as Key Regulators of the Notch Signaling Pathway in Glioblastoma: Diagnostic, Prognostic, and Therapeutic Targets.
    Shahcheraghi SH; Asl ER; Lotfi M; Ayatollahi J; Khaleghinejad SH; Aljabali AAA; Bakshi HA; El-Tanani M; Charbe NB; Serrano-Aroca Á; Mishra V; Mishra Y; Goyal R; Hromić-Jahjefendić A; Uversky VN; Lotfi M; Tambuwala MM
    CNS Neurol Disord Drug Targets; 2024; 23(10):1203-1216. PubMed ID: 38279763
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High-throughput screening uncovers miRNAs enhancing glioblastoma cell susceptibility to tyrosine kinase inhibitors.
    Cunha PP; Costa PM; Morais CM; Lopes IR; Cardoso AM; Cardoso AL; Mano M; Jurado AS; Pedroso de Lima MC
    Hum Mol Genet; 2017 Nov; 26(22):4375-4387. PubMed ID: 28973155
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An Overview of EGFR Mechanisms and Their Implications in Targeted Therapies for Glioblastoma.
    Rodriguez SMB; Kamel A; Ciubotaru GV; Onose G; Sevastre AS; Sfredel V; Danoiu S; Dricu A; Tataranu LG
    Int J Mol Sci; 2023 Jul; 24(13):. PubMed ID: 37446288
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Advances in Targeting the Epidermal Growth Factor Receptor Pathway by Synthetic Products and Its Regulation by Epigenetic Modulators As a Therapy for Glioblastoma.
    Nadeem Abbas M; Kausar S; Wang F; Zhao Y; Cui H
    Cells; 2019 Apr; 8(4):. PubMed ID: 31013819
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting EGFR for treatment of glioblastoma: molecular basis to overcome resistance.
    Taylor TE; Furnari FB; Cavenee WK
    Curr Cancer Drug Targets; 2012 Mar; 12(3):197-209. PubMed ID: 22268382
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting LRIG2 overcomes resistance to EGFR inhibitor in glioblastoma by modulating GAS6/AXL/SRC signaling.
    Dong M; Xiao Q; Hu J; Cheng F; Zhang P; Zong W; Tang Q; Li X; Mao F; He Y; Yu X; Wan F; Lei T; Guo D; Wang B
    Cancer Gene Ther; 2020 Dec; 27(12):878-897. PubMed ID: 31988476
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chronic activation of wild-type epidermal growth factor receptor and loss of Cdkn2a cause mouse glioblastoma formation.
    Acquaviva J; Jun HJ; Lessard J; Ruiz R; Zhu H; Donovan M; Woolfenden S; Boskovitz A; Raval A; Bronson RT; Pfannl R; Whittaker CA; Housman DE; Charest A
    Cancer Res; 2011 Dec; 71(23):7198-206. PubMed ID: 21987724
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Regulation of autophagy by non-coding RNAs in human glioblastoma.
    Molavand M; Ebrahimnezhade N; Kiani A; Yousefi B; Nazari A; Majidinia M
    Med Oncol; 2024 Oct; 41(11):260. PubMed ID: 39375229
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Exosomal transfer of miR-1238 contributes to temozolomide-resistance in glioblastoma.
    Yin J; Zeng A; Zhang Z; Shi Z; Yan W; You Y
    EBioMedicine; 2019 Apr; 42():238-251. PubMed ID: 30917935
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mir-370-3p Impairs Glioblastoma Stem-Like Cell Malignancy Regulating a Complex Interplay between HMGA2/HIF1A and the Oncogenic Long Non-Coding RNA (lncRNA) NEAT1.
    Lulli V; Buccarelli M; Ilari R; Castellani G; De Dominicis C; Di Giamberardino A; D Alessandris QG; Giannetti S; Martini M; Stumpo V; Boe A; De Luca G; Biffoni M; Marziali G; Pallini R; Ricci-Vitiani L
    Int J Mol Sci; 2020 May; 21(10):. PubMed ID: 32443824
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The TICking clock of EGFR therapy resistance in glioblastoma: Target Independence or target Compensation.
    Saleem H; Kulsoom Abdul U; Küçükosmanoglu A; Houweling M; Cornelissen FMG; Heiland DH; Hegi ME; Kouwenhoven MCM; Bailey D; Würdinger T; Westerman BA
    Drug Resist Updat; 2019 Mar; 43():29-37. PubMed ID: 31054489
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CircZNF609 and circNFIX as possible regulators of glioblastoma pathogenesis via miR-145-5p/EGFR axis.
    Ghadami E; Gorji A; Pour-Rashidi A; Noorbakhsh F; Kabuli M; Razipour M; Choobineh H; Maghsudlu M; Damavandi E; Ghadami M
    Sci Rep; 2024 Jun; 14(1):13551. PubMed ID: 38866807
    [TBL] [Abstract][Full Text] [Related]  

  • 17. EGFR-targeted therapy in malignant glioma: novel aspects and mechanisms of drug resistance.
    Lo HW
    Curr Mol Pharmacol; 2010 Jan; 3(1):37-52. PubMed ID: 20030624
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An LXR agonist promotes glioblastoma cell death through inhibition of an EGFR/AKT/SREBP-1/LDLR-dependent pathway.
    Guo D; Reinitz F; Youssef M; Hong C; Nathanson D; Akhavan D; Kuga D; Amzajerdi AN; Soto H; Zhu S; Babic I; Tanaka K; Dang J; Iwanami A; Gini B; Dejesus J; Lisiero DD; Huang TT; Prins RM; Wen PY; Robins HI; Prados MD; Deangelis LM; Mellinghoff IK; Mehta MP; James CD; Chakravarti A; Cloughesy TF; Tontonoz P; Mischel PS
    Cancer Discov; 2011 Oct; 1(5):442-56. PubMed ID: 22059152
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oncogenic EGFR signaling activates an mTORC2-NF-κB pathway that promotes chemotherapy resistance.
    Tanaka K; Babic I; Nathanson D; Akhavan D; Guo D; Gini B; Dang J; Zhu S; Yang H; De Jesus J; Amzajerdi AN; Zhang Y; Dibble CC; Dan H; Rinkenbaugh A; Yong WH; Vinters HV; Gera JF; Cavenee WK; Cloughesy TF; Manning BD; Baldwin AS; Mischel PS
    Cancer Discov; 2011 Nov; 1(6):524-38. PubMed ID: 22145100
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Circular RNA-encoded oncogenic E-cadherin variant promotes glioblastoma tumorigenicity through activation of EGFR-STAT3 signalling.
    Gao X; Xia X; Li F; Zhang M; Zhou H; Wu X; Zhong J; Zhao Z; Zhao K; Liu D; Xiao F; Xu Q; Jiang T; Li B; Cheng SY; Zhang N
    Nat Cell Biol; 2021 Mar; 23(3):278-291. PubMed ID: 33664496
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.